We often assume that once a drug goes generic or gets “negotiated” by Medicare, the price will drop forever. In 2026, the opposite is happening for many seniors. While the Inflation Reduction Act has officially capped total out-of-pocket spending at $2,100, insurers have aggressively restructured their formularies to protect their profits against this new liability.
To manage the new cap, plans have raised the standard deductible to $615 and moved popular drugs to higher “coinsurance” tiers. They have also excluded older brand-name drugs in favor of specific biosimilars. If you are on auto-refill, you might not notice the change until the credit card receipt prints. Here are the seven medications seeing significant price hikes or coverage gaps for seniors this winter.
1. Eliquis (Apixaban)
This blood thinner is one of the first 10 drugs to have a “Maximum Fair Price” negotiated by Medicare for 2026. However, the lower price paid by the government does not automatically translate to a lower copay for you. Many Part D plans have responded to the new negotiation rules by adjusting their formularies. Some industry analysts warn of “ripple effects” where plans may move negotiated drugs like Eliquis to non-preferred tiers to manage their costs. If your plan made this switch, your flat $45 copay could turn into a coinsurance charge of 25% until you meet the new $2,100 cap.
2. Humira (Adalimumab)
The market is now flooded with cheaper “biosimilar” versions of this arthritis drug. Consequently, major Pharmacy Benefit Managers (PBMs) like CVS Caremark and Express Scripts have removed brand-name Humira from their 2026 formularies. If you insist on staying on the original brand, you will likely pay the full cash price. Furthermore, plans often cover only one specific biosimilar (like Hadlima or Hyrimoz). If your doctor writes the prescription for the “wrong” biosimilar, it will be denied. You must verify exactly which version your plan covers before you head to the pharmacy.
3. Symbicort (Budesonide/Formoterol)
Inhalers are facing a wave of “authorized generic” shifts. The brand-name Symbicort has been dropped by many plans in 2026 in favor of its generic equivalent. While generics are usually cheaper, some plans have placed this specific generic on Tier 4 (Non-Preferred Drug). This means you pay a percentage of the cost rather than a flat copay. For many seniors, paying 40% coinsurance on the generic price is actually higher than the flat copay they paid for the brand name last year.
4. Ozempic (Semaglutide)
The crackdown on “off-label” use has intensified. Plans are rigorously auditing prescriptions for Ozempic to ensure it is for Type 2 Diabetes, not just weight loss. While Medicare is launching a pilot program later in 2026 to cover GLP-1s for obesity, strict rules remain in place for early 2026. If your renewal comes up and your chart lacks a specific diabetes diagnosis code, coverage will be denied. You could be forced to pay the full list price, which remains over $900 a month.
5. Synthroid (Levothyroxine)
Many seniors prefer the brand-name thyroid medication because they are sensitive to dosage changes. In 2026, plans are widening the “penalty” for choosing brand over generic. This is often called a “DAW 2” (Dispense as Written) penalty. If you request Synthroid when a generic is available, you pay the Tier 3 copay PLUS the difference in cost between the brand and the generic. This difference can triple your monthly out-of-pocket cost compared to 2025.
6. Lantus (Insulin Glargine)
While the cost of insulin is capped at $35 per month, that cap only applies to covered insulin products. Plans change their “preferred” insulin brands annually to chase rebates. Your plan may have swapped Lantus for Basaglar or Semglee this year. If you refill Lantus without checking, it may be considered “non-formulary.” Non-formulary drugs are not protected by the $35 cap in all cases, leaving you to face the full retail price unless you switch brands.
7. Generic Antibiotics (Amoxicillin/Doxycycline)
Shortages and supplier price hikes have pushed even basic antibiotics into higher tiers. Some Part D plans have moved “multisource” generics from Tier 1 ($0-$5 copay) to Tier 2 ($10-$20 copay). While a $10 increase seems small, it represents a 200% price hike for a standard infection treatment. For seniors on fixed incomes filling multiple prescriptions, these small tier creeps add up quickly.
Check Your “Annual Notice of Change”
Did you throw away the thick packet your insurer sent in November? That was the Annual Notice of Change (ANOC). Dig it out or log in online immediately. Search for your specific drugs. If a drug has moved to a higher tier or is now excluded, ask your doctor to rewrite the prescription for the “Preferred” alternative. In 2026, loyalty to a specific pill brand is a luxury most retirement budgets cannot afford.
Did your blood thinner copay double this month? Leave a comment below—tell us which plan moved your drug to a higher tier!
